Germany’s BioNTech has presented positive Phase I/II on its CAR-T cell therapy candidate BNT211 in advanced solid tumors at the European Society of Medical Onco 24 October 2023
At the 2023 annual congress of the European Society of Medical Oncology (ESMO), Johnson & Johnson has presented important new data for Rybrevant (amivantamab-vm 24 October 2023
The TROPION-Lung01 Phase III trial has yielded positive data for datopotamab deruxtecan (Dato-DXd), an investigational TROP2-directed antibody drug conjugate (A 23 October 2023
Bristol Myers Squibb has announced the first presentation of results from the Phase III CheckMate -901 trial involving Opdivo (nivolumab) at the 2023 European S 23 October 2023
At the annual congress of the European Society for Medical Oncology (ESMO), Seagen and Astellas Pharma have presented detailed data from the Phase III EV-302 st 23 October 2023
Britain’s largest drugmaker, AstraZeneca, has reported positive results from a planned interim analysis of the MATTERHORN Phase III trial. 20 October 2023
No cancer conference would be complete without Merck & Co presenting a mountain of data on its blockbuster anti-PD-1 therapy Keytruda (pembrolizumab). 20 October 2023
Nearly five months have passed since the Annual Meeting of the American Society of Clinical Oncology (ASCO) took place, and cancer-focused drugmakers are ready 19 October 2023
With the final presentations of this year’s meeting of the European Society of Medical Oncology (ESMO 22) in full swing, there is a lot for the scientific commu 12 September 2022
American drugmaker Eli Lilly has provided updated results from the MONARCH 3 trial, at the annual meeting of the European Society of Medical Oncology (ESMO 22). 12 September 2022
Long-term follow-up results from the PAOLA-1 and SOLO-1 Phase III trials of Lynparza (Olaparib), with or without bevacizumab, have demonstrated clinically meani 9 September 2022
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.